SSY Group Ltd
HKEX:2005
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.46
5.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
SSY Group Ltd
Cost of Revenue
SSY Group Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SSY Group Ltd
HKEX:2005
|
Cost of Revenue
-HK$3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-17%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cost of Revenue
-HK$4.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Cost of Revenue
-¥7.5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cost of Revenue
-¥4.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-9%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cost of Revenue
-HK$314B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cost of Revenue
-$356.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-26%
|
|
SSY Group Ltd
Glance View
SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
See Also
What is SSY Group Ltd's Cost of Revenue?
Cost of Revenue
-3B
HKD
Based on the financial report for Jun 30, 2024, SSY Group Ltd's Cost of Revenue amounts to -3B HKD.
What is SSY Group Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-17%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for SSY Group Ltd have been -16% over the past three years , -12% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
